Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI)

NANot yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myocardial Infarction
Interventions
DRUG

PCSK9 inhibitor

The patient used Trastuzumab 150mg within 24 hours before or after PCI, and then every two weeks for 12 months

DRUG

Statin+ezetimibe

The patient used statins and ezetimibe within 24 hours before or after PCI, and then once a day for 12 months

BEHAVIORAL

Blood lipid levels meet the recommended guidelines

Early use of intensified lipid-lowering therapy during hospitalization led to a rapid decrease in blood lipids and met the recommended guidelines.

BEHAVIORAL

Blood lipid levels don't meet the recommended guidelines

The patient did not receive intensified lipid-lowering treatment during hospitalization or did not meet the recommended guidelines for blood lipids

Trial Locations (2)

100853

Chinese PLA General Hospital, Beijing

Unknown

Chinese PLA General Hospital [, Beijing

All Listed Sponsors
lead

Yun Dai Chen

OTHER

NCT06854523 - Assessing Coronary Non-Culprit Plaque Early with Start of PCSK9 Inhibitors in Acute Myocardial Infarction (ACCESS-AMI) | Biotech Hunter | Biotech Hunter